{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:58:15Z","timestamp":1761544695466,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.japh.2022.12.025","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T22:34:57Z","timestamp":1671748497000},"page":"904-908.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics and health service use of Medicaid-insured individuals filling naloxone under a standing order in Louisiana"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5682-9625","authenticated-orcid":false,"given":"Olivia K.","family":"Sugarman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarrod","family":"Breithaupt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5610-8382","authenticated-orcid":false,"given":"Marcus A.","family":"Bachhuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2021","series-title":"Drug Poisoning Mortality, by State and Race and Ethnicity: United States, 2019","author":"Mini\u00f1o","key":"10.1016\/j.japh.2022.12.025_bib1"},{"year":"2016","series-title":"Public Policy Statement on the Use of Naloxone for the Prevention of Opioid Overdose Deaths","key":"10.1016\/j.japh.2022.12.025_bib3"},{"issue":"1","key":"10.1016\/j.japh.2022.12.025_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","article-title":"CDC Guideline for Prescribing Opioids for Chronic Pain \u2014 United States, 2016","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Recommendations and Reports"},{"key":"10.1016\/j.japh.2022.12.025_bib6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drugalcdep.2018.05.014","article-title":"Do naloxone access laws increase outpatient naloxone prescriptions? Evidence from Medicaid","volume":"190","author":"Gertner","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.japh.2022.12.025_bib7","article-title":"Association between a state law allowing pharmacists to dispense naloxone without a prescription and naloxone dispensing rates","volume":"3","author":"Gangal","year":"2020","journal-title":"JAMA Netw"},{"key":"10.1016\/j.japh.2022.12.025_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drugalcdep.2018.04.020","article-title":"State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies","volume":"189","author":"Xu","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"10.1016\/j.japh.2022.12.025_bib9","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jamainternmed.2019.0272","article-title":"Association between State Laws Facilitating Pharmacy Distribution of Naloxone and Risk of Fatal Overdose","volume":"179","author":"Abouk","year":"2019","journal-title":"JAMA Internal Med"},{"issue":"1","key":"10.1016\/j.japh.2022.12.025_bib13","article-title":"Association of Medicaid wexpansion With opioid overdose mortality in the United States","volume":"3","author":"Kravitz-Wirtz","year":"2020","journal-title":"JAMA Net"},{"issue":"9","key":"10.1016\/j.japh.2022.12.025_bib14","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/add.14634","article-title":"The impact of expanded Medicaid eligibility on access to naloxone.","volume":"114","author":"Frank","year":"2019","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.japh.2022.12.025_bib15","article-title":"Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion","volume":"1","author":"Saloner","year":"2018","journal-title":"JAMA Netw"},{"author":"Orgera","key":"10.1016\/j.japh.2022.12.025_bib17"},{"issue":"11","key":"10.1016\/j.japh.2022.12.025_bib19","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/MLR.0000000000000805","article-title":"Trends in opioid-related inpatient stays shifted after the US transitioned to ICD-10-CM diagnosis coding in 2015","volume":"55","author":"Heslin","year":"2017","journal-title":"Med Care"},{"key":"10.1016\/j.japh.2022.12.025_bib20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","article-title":"Long-term retention in office based opioid treatment with buprenorphine","volume":"74","author":"Weinstein","year":"2017","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"10.1016\/j.japh.2022.12.025_bib21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/08897077.2018.1443541","article-title":"Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program","volume":"39","author":"Bachhuber","year":"2018","journal-title":"Subst Abus"},{"issue":"6","key":"10.1016\/j.japh.2022.12.025_bib23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.amepre.2018.12.003","article-title":"National 90-Day Readmissions After Opioid Overdose Discharge","volume":"56","author":"Peterson","year":"2019","journal-title":"Am J Prev Med"},{"issue":"4","key":"10.1016\/j.japh.2022.12.025_bib25","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/ADM.0000000000000492","article-title":"Naloxone availability and pharmacy staff knowledge of standing order for naloxone in Pennsylvania pharmacies","volume":"13","author":"Graves","year":"2019","journal-title":"J Addict Med"},{"key":"10.1016\/j.japh.2022.12.025_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108912","article-title":"Predictors of having naloxone in urban and rural Oregon findings from NHBS and the OR-HOPE study","volume":"227","author":"Lipira","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1016\/j.japh.2022.12.025_bib27","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/YCO.0000000000000337","article-title":"Gender differences in prescription opioid use","volume":"30","author":"Serdarevic","year":"2017","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.japh.2022.12.025_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.japh.2017.01.002","article-title":"Implementing an overdose education and naloxone distribution program in a health system","author":"Devries","year":"2017","journal-title":"J Am Pharm Assoc. Published online"},{"issue":"9","key":"10.1016\/j.japh.2022.12.025_bib29","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/add.14635","article-title":"Do electronic health record prompts increase take-home naloxone administration for emergency department patients after an opioid overdose?","volume":"114","author":"Marino","year":"2019","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.japh.2022.12.025_bib30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.7326\/M15-2771","article-title":"Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long- Term opioid therapy for pain","volume":"165","author":"Coffin","year":"2016","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.japh.2022.12.025_bib31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11606-016-3911-z","article-title":"Acceptability of naloxone co-prescription among primary care providers treating patients on long-term opioid therapy for pain","volume":"32","author":"Behar","year":"2017","journal-title":"J Gen Intern Med"},{"issue":"4","key":"10.1016\/j.japh.2022.12.025_bib32","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/08897077.2016.1179704","article-title":"Co-prescription of naloxone as a universal precautions model for patients on chronic opioid therapy\u2014Observational study","volume":"37","author":"Takeda","year":"2016","journal-title":"Substance Abuse"},{"issue":"1","key":"10.1016\/j.japh.2022.12.025_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/08897077.2018.1518836","article-title":"Development and evaluation of a pilot overdose education and naloxone distribution program for hospitalized general medical patients","volume":"40","author":"Jakubowski","year":"2019","journal-title":"Substance Abuse"},{"key":"10.1016\/j.japh.2022.12.025_bib34","doi-asserted-by":"crossref","first-page":"102827","DOI":"10.1016\/j.drugpo.2020.102827","article-title":"Applying the capability, opportunity, motivation, and behavior model to identify opportunities to increase pharmacist comfort dispensing naloxone in Texas: A structural equation modeling approach","volume":"83","author":"Varisco","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"12","key":"10.1016\/j.japh.2022.12.025_bib35","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s11606-015-3394-3","article-title":"Overdose education and naloxone for patients prescribed opioids in primary care: A qualitative study of primary care staff","volume":"30","author":"Binswanger","year":"2015","journal-title":"J Gen Intern Med"},{"issue":"2","key":"10.1016\/j.japh.2022.12.025_bib36","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.japh.2017.01.013","article-title":"Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states","volume":"57","author":"Green","year":"2017","journal-title":"J Am Pharm Assoc"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122004216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122004216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:52:24Z","timestamp":1761544344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319122004216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1544319122004216"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2022.12.025","relation":{},"ISSN":["1544-3191"],"issn-type":[{"type":"print","value":"1544-3191"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics and health service use of Medicaid-insured individuals filling naloxone under a standing order in Louisiana","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2022.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}